Under the terms of the license option agreement, originally announced in October 2021, Voyager previously received a $30 million upfront payment and is entitled to receive a $10 million option exercise payment. Voyager is eligible to receive potential future development, regulatory and commercialization milestone payments of up to $115 million, sales milestones of up to $175 million, and mid- to high-single-digit tiered royalties in connection with Pfizer’s use of its capsid in development and commercialization of a gene therapy for a rare neurologic target.
Wynn Resorts Has An Upside To Estimates, Says Bullish Analyst
Wynn Resorts, Limited (NASDAQ: WYNN) shares have been in focus amid the post-COVID-19 pandemic rebound in the gambling industry.
